Hunt J Porter, Zhao Emily Long, Soltani Mehran, Frei Madison, Nelson J Andrew D, Bundy Bradley C
Department of Chemical Engineering, Brigham Young University, Provo, UT, USA.
Synth Syst Biotechnol. 2019 Dec 13;4(4):220-224. doi: 10.1016/j.synbio.2019.11.003. eCollection 2019 Dec.
An "endotoxin-free" -based cell-free protein synthesis system has been reported to produce therapeutic proteins rapidly and on-demand. However, preparation of the most complex CFPS reagent - the cell extract - remains time-consuming and labor-intensive because of the relatively slow growth kinetics of the endotoxin-free ClearColiBL21(DE3) strain. Here we report a streamlined procedure for preparing cell extract from ClearColi™ using auto-induction media. In this work, the term auto-induction describes cell culture media which eliminates the need for manual induction of protein expression. Culturing Clearcoli™ cells in autoinduction media significantly reduces the hands-on time required during extract preparation, and the resulting "endotoxin-free" cell extract maintained the same cell-free protein synthesis capability as extract produced with traditional induction as demonstrated by the high-yield expression of crisantaspase, an FDA approved leukemia therapeutic. It is anticipated that this work will lower the barrier for researchers to enter the field and use this technology as the method to produce endotoxin-free -based extract for CFPS.
据报道,一种基于“无内毒素”的无细胞蛋白质合成系统能够快速且按需生产治疗性蛋白质。然而,由于无内毒素的ClearColiBL21(DE3)菌株生长动力学相对较慢,制备最复杂的无细胞蛋白质合成试剂——细胞提取物——仍然耗时且费力。在此,我们报告一种使用自诱导培养基从ClearColi™制备细胞提取物的简化程序。在这项工作中,术语“自诱导”指的是无需手动诱导蛋白质表达的细胞培养基。在自诱导培养基中培养Clearcoli™细胞显著减少了提取物制备过程中所需的实际操作时间,并且所得到的“无内毒素”细胞提取物保持了与传统诱导产生的提取物相同的无细胞蛋白质合成能力,这通过FDA批准的白血病治疗药物crisantaspase的高产表达得以证明。预计这项工作将降低研究人员进入该领域的门槛,并将此技术用作生产用于无细胞蛋白质合成的无内毒素提取物的方法。